(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;hydron

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;hydron
• 化学式: C13H25N4O3S+
• 分子量: 317.43
• InChiKey: BLJRIMJGRPQVNF-JTQLQIEISA-O

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES
  申请人：Yale University

  公开号：EP2178502A2

  公开（公告）日：2010-04-28
• SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES
  申请人：Lavik Erin

  公开号：US20100261646A1

  公开（公告）日：2010-10-14

  Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (TOP) in the eye. In one embodiment, the microspheres are formed from polylactide-co-glycolide (“PLGA”); in another embodiment, the microspheres are formed from a blend PLGA and poly lactic acid (“PLA”). Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time. The combination of drug loading and release rate, as well as the minimization of initial burst release, result in prolonged release of a higher amount of drug.
• DENDRIMER HYDROGELS
  申请人：Yang Hu

  公开号：US20110189291A1

  公开（公告）日：2011-08-04

  Photoactivatable dendrimers and hydrogels formed therefrom include dendrimers to which polymer chains (e.g. polyethylene glycol, PEG) have been conjugated; and reactive photoactivatable groups attached to terminal functional groups of the polymer chains (e.g. hydroxyls of PEG). Exposure to a suitable wavelength of light activates the photoactivatable groups, which then crosslink with one another, thereby forming a hydrogel. The hydrogel may also include one or more agents of interest; or, in some embodiments, nanoparticles containing one or more agents of interest may be dispersed in the hydrogel. These formulations are well-suited for sustained or prolonged delivery of active agents, e.g. for the treatment of glaucoma by the sustained delivery of anti-glaucoma agents directly to the eye.
• COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS, INFLAMMATION, AND METABOLIC DYSREGULATION
  申请人：Finley Jahahreeh

  公开号：US20130273175A1

  公开（公告）日：2013-10-17

  The present invention relates to methods and formulations for the prevention or treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation. Specifically, the present invention comprises compositions and methods that increase mitochondrial biogenesis, alleviate inflammation, and increase the level of endogenous enzymatic and non-enzymatic antioxidants in a subject.
• US8492334B2
  申请人：——

  公开号：US8492334B2

  公开（公告）日：2013-07-23